Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents

被引:89
作者
Dupuis, L. Lee
Taddio, Anna
Kerr, Elizabeth N.
Kelly, Andrea
MacKeigan, Linda
机构
[1] Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada
[3] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada
[4] Hosp Sick Children, Div Neonatol, Toronto, ON M5G 1X8, Canada
[5] Hosp Sick Children, Div Populat Hlth Sci, Inst Res, Toronto, ON M5G 1X8, Canada
[6] Univ Toronto, Fac Pharm, Toronto, ON, Canada
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 09期
关键词
Pediatric Nausea Assessment Tool; PeNAT; nausea; children; antineoplastic-induced nausea; pediatric oncology;
D O I
10.1592/phco.26.9.1221
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Study Objective. To develop and validate. an instrument to assess nausea intensity in children aged 4-18 years. Design. Prospective, descriptive study. Setting. Tertiary-quaternary, university-affiliated pediatric hospital. Patients. Four pediatric inpatient groups (177 patients): group 1 (107), those receiving cancer chemotherapy; group 2 (24), those receiving cancer chemotherapy before hematopoietic stem cell transplantation; group 3 (23), those with cancer who were not receiving cancer chemotherapy; and group 4 (23), those without cancer. Intervention. We developed a scale with a standard script for administration, the Pediatric Nausea Assessment Tool (PeNAT). Revisions were made after face validity testing with clinicians and parents, and pilot testing with 15 inpatients undergoing chemotherapy. Measurements and Main Results. The PeNAT scores were obtained 4-24 hours after chemotherapy in groups 1 and 2. Dietary intake scores and number of emetic episodes were recorded for the 4 hours before PeNAT administration for all patients in group 2 and 36 patients in group 1. Parents of a subset of patients made an independent assessment of their child's nausea and pain intensities immediately before PeNAT administration. Reliability was evaluated in groups I and 2 by correlating the first and second (obtained 1 hr after the first) PeNAT scores. Construct validity was evaluated by comparing PeNAT scores in groups 1-4. Criterion-related validity was evaluated by correlating PeNAT scores with emetic episodes and dietary intake. Convergent and discriminant validity were evaluated by correlating PeNAT scores with parental assessments of nausea and pain. Significant differences in PeNAT scores were noted among the study groups (p=0.035). Moderate correlation was noted between the first and second PeNAT scores (Spearman p = 0.649). The PeNAT scores correlated modestly with emetic episodes (Spearman p = 0.322) but not with dietary intake (Spearman p = -0.217). Children's PeNAT scores correlated moderately with their parents' assessment of nausea (Spearman rho = 0.442), whereas little correlation was seen between children's PeNAT scores and parents' assessment of pain (Spearman p = 0. 167). Conclusion. The PeNAT is a new instrument that can be used by children to assess nausea intensity.
引用
收藏
页码:1221 / 1231
页数:11
相关论文
共 36 条
[1]
RANDOMIZED DOUBLE-BLIND CROSSOVER ONDANSETRON-DEXAMETHASONE VERSUS ONDANSETRON-PLACEBO STUDY FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC-PATIENTS WITH MALIGNANCIES [J].
ALVAREZ, O ;
FREEMAN, A ;
BEDROS, A ;
CALL, SK ;
VOLSCH, J ;
KALBERMATTER, O ;
HALVERSON, J ;
CONVY, L ;
COOK, L ;
MICK, K ;
ZIMMERMAN, G .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1995, 17 (02) :145-150
[2]
[Anonymous], 1998, REVISED COMMON TOXIC
[3]
Developmental differences in children's use of rating scales [J].
Chambers, CT ;
Johnston, C .
JOURNAL OF PEDIATRIC PSYCHOLOGY, 2002, 27 (01) :27-36
[4]
Champion GD, 1998, PROG PAIN RES MANAG, V10, P123
[5]
ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[6]
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists [J].
deBoerDennert, M ;
deWit, R ;
Schmitz, PIM ;
Djontono, J ;
vanBeurden, V ;
Stoter, G ;
Verweij, J .
BRITISH JOURNAL OF CANCER, 1997, 76 (08) :1055-1061
[7]
ASSESSMENT OF NAUSEA [J].
DELFAVERO, A ;
ROILA, F ;
BASURTO, C ;
MINOTTI, V ;
BALLATORI, E ;
PATOIA, L ;
TONATO, M ;
TOGNONI, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (02) :115-120
[8]
DELFAVERO A, 1992, BRIT J CANCER, V66, pS69
[9]
RANDOMIZED COMPARISON OF ONDANSETRON AND METOCLOPRAMIDE PLUS DEXAMETHASONE FOR CHEMOTHERAPY-INDUCED EMESIS [J].
DICK, GS ;
MELLER, ST ;
PINKERTON, CR .
ARCHIVES OF DISEASE IN CHILDHOOD, 1995, 73 (03) :243-245
[10]
Delayed nausea and vomiting in children receiving antineoplastics [J].
Dupuis, LL ;
Lau, R ;
Greenberg, ML .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (02) :115-121